Drug intelligence / Profile preview

Lysicon V

Development stage: Unknown
Lead developer: Exeltis
Modality: Small Molecules
Administration: Oral

Overview

Lysicon V is a pediatric nutritional supplement marketed by Ordain Health Care, a division of Exeltis India. It is formulated as a syrup containing a combination of the essential amino acid L-Lysine hydrochloride and a comprehensive B-vitamin complex, including Thiamine (B1), Riboflavin (B2), Niacinamide (B3), D-Panthenol (B5), Pyridoxine (B6), and Cyanocobalamin (B12). The product is primarily indicated as an appetite stimulant and growth promoter for children, helping to address nutritional deficiencies and support healthy physical and cognitive development. L-Lysine facilitates protein synthesis and calcium absorption, while the B-vitamins act as vital co-enzymes in energy metabolism and nervous system maintenance.

Brand names: Lysicon V
Other names: Lysicon-V

Beyond the preview

Go deeper on Lysicon V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysicon V.

Explore the full profile